Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
about
Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Lenalidomide in multiple myeloma: current experimental and clinical data.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaNovel strategies for blood stem cell mobilization: special focus on plerixafor.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Novel immunomodulatory compounds in multiple myeloma.The evolving role of plerixafor in hematopoietic progenitor cell mobilization.Current clinical indications for plerixaforControversies in multiple myeloma: to transplant or not?Novel Induction Regimens in Multiple Myeloma.Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma.Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.Plerixafor for autologous CD34 cell mobilization.Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting.Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center.Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization
P2860
Q33404007-FAEA1837-2F65-49E1-9053-70D3AEFC8A59Q33408698-55BC3793-CCF3-444B-867D-90DF4D6D185EQ33411277-17F858AD-EF5B-4FC2-A79F-03B5336B855DQ34074803-D938032C-2F4A-4FE9-B171-E4B641C76F12Q34253548-1DD5C751-E09A-4445-BBB0-5F5B0E364C64Q36012111-F9E99347-F74B-46EB-A851-F21289F9CFFFQ37909447-AC6540DE-F516-4B50-9A39-FFFC2ADF9DAAQ37921284-95E82947-43C8-4E25-B823-6C79099E801AQ38031989-10CEDB4F-9764-4168-B135-B9B149F52836Q38069614-F6918F5C-FD65-456D-ACDB-4763E2F8CAFBQ38077807-0958A4D9-206B-44DF-9C79-ECEF6F356155Q38177784-2E53EED7-B784-4A1B-81BA-CA2DC7309458Q38242006-64329A2A-B90C-4068-863C-0A78906CEB21Q38567017-13188E7E-97E1-4F91-8975-95B1F78345BEQ38859426-246BA2C3-9D34-4206-AAF0-E9973E105B2AQ39478021-E65C4277-6693-4EF8-8DFC-C8931CA50429Q39724267-45D37641-B7EE-4B8C-83FD-C6F452163C74Q40543905-FB1779DE-4441-4C05-BAFE-BC7F716A3BA4Q41267193-7BA3999A-2593-428A-8EB1-F9582EB9C7C6Q42204448-DCA86557-4683-4102-A3BB-C57AD9A71C1AQ47914097-044ACEC2-5881-454D-BAF3-4B3155FA64B8Q50092819-A02EBC50-7779-4DF5-853E-E48C0F1490E6Q51385709-133474AB-CF9F-4660-9DD0-963B9B8A7AE3Q53117359-E3B55E44-4908-4842-9B40-B8BA58346093Q58299703-884AD64C-13EA-4070-AEC4-22E44CF71798
P2860
Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Plerixafor (Mozobil) for stem ...... sly treated with lenalidomide.
@en
type
label
Plerixafor (Mozobil) for stem ...... sly treated with lenalidomide.
@en
prefLabel
Plerixafor (Mozobil) for stem ...... sly treated with lenalidomide.
@en
P2093
P2860
P356
P1476
Plerixafor (Mozobil) for stem ...... sly treated with lenalidomide.
@en
P2093
G Calandra
I N M Micallef
P A McSweeney
P J Gandhi
S Marulkar
P2860
P2888
P304
P356
10.1038/BMT.2010.118
P407
P577
2010-05-17T00:00:00Z
P6179
1007986726